Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) EBITDA: 2020-2025

Historic EBITDA for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to -$11.0 million.

  • Insight Molecular Diagnostics' EBITDA rose 18.25% to -$11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.3 million, marking a year-over-year decrease of 40.66%. This contributed to the annual value of -$61.0 million for FY2024, which is 142.84% down from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' EBITDA stood at -$11.0 million, which was down 12.25% from -$9.8 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' EBITDA's 5-year high stood at $5.8 million during Q1 2023, with a 5-year trough of -$35.7 million in Q4 2021.
  • In the last 3 years, Insight Molecular Diagnostics' EBITDA had a median value of -$9.3 million in 2024 and averaged -$10.4 million.
  • In the last 5 years, Insight Molecular Diagnostics' EBITDA crashed by 469.33% in 2021 and then soared by 159.12% in 2023.
  • Over the past 5 years, Insight Molecular Diagnostics' EBITDA (Quarterly) stood at -$35.7 million in 2021, then surged by 67.35% to -$11.6 million in 2022, then crashed by 38.90% to -$16.2 million in 2023, then tumbled by 107.84% to -$33.6 million in 2024, then grew by 18.25% to -$11.0 million in 2025.
  • Its EBITDA stands at -$11.0 million for Q3 2025, versus -$9.8 million for Q2 2025 and -$6.8 million for Q1 2025.